Respiratory failure & ventilation
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission
Main finding · Association of baseline lung injury biomarkers with progression to respiratory failure or deathResult — go to the resultOdds ratio 1.85 95% CI 1.61–2.12Authors' conclusion
Baseline levels of plasma lung injury biomarkers are significantly associated with progression to respiratory failure or death among hospitalized COVID-19 patients without respiratory failure at admission.
Study context
- Population
- Adults hospitalised with COVID-19 pneumonia without respiratory failure at admission (<20 L/min supplemental oxygen) in the ACTIV-3/TICO platform trial
- Participants
- 405 vs 405
- Comparison
- Baseline lung injury biomarkers: cases vs matched controls
- Casesn = 405
- Controlsn = 405reference
- Outcome
- Association of baseline lung injury biomarkers with progression to respiratory failure or death
Methodological detailsmatched 1:1 on age, baseline oxygen requirement, immunomodulator use, and study arm, nested in the ACTIV-3/TICO platform trial
- Matched 1:1 on age, baseline oxygen requirement, immunomodulator use, and study arm
- Nested in the ACTIV-3/TICO platform trial
Main finding
As reported in the abstract
Odds ratio
1.85
95% CI 1.61–2.12
sRAGE (per doubling)
OR 1.85 (95% CI 1.61–2.12)
Per doubling, as printed
Observational data: associations, not effects.
Further findings
Independent association (multivariate model, forward selection)
- sRAGE, IL-6 and C-reactive protein (CRP) independently associated with progression; sRAGE strongest
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission. Crit Care Med. Published 26 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →